DK2055311T3 - Fremgangsmåde til fremstilling af levende koppevaccine - Google Patents

Fremgangsmåde til fremstilling af levende koppevaccine Download PDF

Info

Publication number
DK2055311T3
DK2055311T3 DK07792040.3T DK07792040T DK2055311T3 DK 2055311 T3 DK2055311 T3 DK 2055311T3 DK 07792040 T DK07792040 T DK 07792040T DK 2055311 T3 DK2055311 T3 DK 2055311T3
Authority
DK
Denmark
Prior art keywords
cells
solution
strain
viral
vaccine
Prior art date
Application number
DK07792040.3T
Other languages
English (en)
Inventor
Shigeru Morikawa
Tomomi Kanehara
Hiroyuki Yokote
Kunio Ohkuma
Masahiko Kuranaga
Original Assignee
The Chemo-Sero-Therapeutic Res Inst
Japan As Represented By Director General Of Nat Inst Of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo-Sero-Therapeutic Res Inst, Japan As Represented By Director General Of Nat Inst Of Infectious Diseases filed Critical The Chemo-Sero-Therapeutic Res Inst
Application granted granted Critical
Publication of DK2055311T3 publication Critical patent/DK2055311T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Claims (3)

1. Fremgangsmåde til fremstilling af en lægemiddelsubstans af en vaccine indeholdende som aktiv bestanddel svækket vacciniavirus LC16m8-stamme med et revertant-indholdsforhold på 3% eller derunder, der omfatter følgende trin (1) til (4) eller (1) til (5): (1) Pode en opløsning af LC16m8-stammen ved sådant et område på MOI for at undgå kontamination af revertanter (MSP-stamme) til 1 til n beholdere, hvor n er et heltal, af dyreceller og inkubere dem; (2) Fortynde en del af den dyrkede opløsning fra hver beholder og pode den fortyndede opløsning til RK-13-celler og til Vero-celler ved et viralt indhold på 1 x 104 PFU eller derover og inkubere dem; (3) Vælge beholdere der indeholder en dyrket opløsning der danner plak i RK-13-celler men ikke danner plak i Vero-celler og opsamle og sammenlægge hver viral opløsning fra cellerne og/eller dyrket opløsning opnået fra valgte beholdere; (4) Pode den sammenlagte virale opløsning opnået i (3) til dyre-celler ved en MOI på 0,1 til 1 og opsamle en viral opløsning fra cellerne og/eller dyrket opløsning; og (5) Pode den opsamlede virale opløsning og/eller dyrkede opløsning, opnået i (4) til dyreceller ved en MOI på 0,1 til 1, inkubere cellerne, og opsamle en viral opløsning fra cellerne og/eller dyrkningsopløsningen.
2. Fremgangsmåden ifølge krav 1, hvor dyrecellerne er primærceller.
3. Fremgangsmåden ifølge krav 2, hvor primærcellerne er afledt fra kaninnyrer.
DK07792040.3T 2006-08-07 2007-08-06 Fremgangsmåde til fremstilling af levende koppevaccine DK2055311T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006214017 2006-08-07
PCT/JP2007/065370 WO2008018411A1 (fr) 2006-08-07 2007-08-06 Procédé de production d'un vaccin vivant antivariolique

Publications (1)

Publication Number Publication Date
DK2055311T3 true DK2055311T3 (da) 2017-07-24

Family

ID=39032941

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07792040.3T DK2055311T3 (da) 2006-08-07 2007-08-06 Fremgangsmåde til fremstilling af levende koppevaccine

Country Status (9)

Country Link
US (1) US8030020B2 (da)
EP (1) EP2055311B1 (da)
JP (1) JP5326155B2 (da)
KR (1) KR101390971B1 (da)
CN (1) CN101557824B (da)
AU (1) AU2007282612B2 (da)
CA (1) CA2662569C (da)
DK (1) DK2055311T3 (da)
WO (1) WO2008018411A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102023207B1 (ko) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 동결건조 바이러스 제형
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
TW201307561A (zh) * 2011-04-29 2013-02-16 腫瘤防治生化科技公司 使用凝膠滲透層析法純化病毒之方法
PL2739293T3 (pl) * 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Sposoby i kompozycje wytwarzania wirusa krowianki
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695935B2 (ja) 1986-07-31 1994-11-30 東燃株式会社 ワクチニアウイルス株
AU2003289223A1 (en) * 2003-12-05 2005-06-24 Hokkaido Technology Licensing Office Co., Ltd. Highly safe smallpox vaccine virus and vaccinia virus vector

Also Published As

Publication number Publication date
CN101557824B (zh) 2012-01-25
CA2662569A1 (en) 2008-02-14
EP2055311B1 (en) 2017-06-21
JP5326155B2 (ja) 2013-10-30
AU2007282612B2 (en) 2012-08-23
US20100183672A1 (en) 2010-07-22
WO2008018411A1 (fr) 2008-02-14
EP2055311A1 (en) 2009-05-06
AU2007282612A1 (en) 2008-02-14
EP2055311A4 (en) 2010-09-01
AU2007282612A2 (en) 2009-07-02
KR101390971B1 (ko) 2014-05-02
CA2662569C (en) 2017-01-03
KR20090074731A (ko) 2009-07-07
JPWO2008018411A1 (ja) 2009-12-24
CN101557824A (zh) 2009-10-14
US8030020B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
Levitt et al. Development of an attenuated strain of chikungunya virus for use in vaccine production
Weck et al. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68
Ou et al. Infectious laryngotracheitis virus in chickens
Kroon et al. Zoonotic Brazilian Vaccinia virus: from field to therapy
Wiktor et al. Suppression of cell-mediated immunity by street rabies virus.
DK2055311T3 (da) Fremgangsmåde til fremstilling af levende koppevaccine
Li et al. Recombinant duck enteritis viruses expressing major structural proteins of the infectious bronchitis virus provide protection against infectious bronchitis in chickens
TWI570240B (zh) 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
Empig et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge
Kapoor et al. Equine herpesviruses: a brief review
CN110218706A (zh) 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用
CN100535108C (zh) 活的减毒的鲤鱼dna病毒及其用途
Xu et al. Generation and evaluation of a recombinant goose origin Newcastle disease virus expressing Cap protein of goose origin avastrovirus as a bivalent vaccine in goslings
Schat et al. Chicken infectious anemia and circovirus infections in commercial flocks
NO153010B (no) Fremgngsmaate for fremstilling av vaksine mot newcastle-sykdom i fjaerkre
Scott et al. A biologic comparison of two strains of Herpesvirus hominis
CN1295339C (zh) 减毒痘苗病毒天坛株载体及制备方法和应用
CN1654666A (zh) 减毒痘苗病毒天坛株载体及制备方法和应用
Khan et al. Hydropericardium syndrome in Pakistan: a review
Kumar et al. Selection of a Recombinant Marek's Disease Virus In Vivo Through Expression of the Marek's EcoRI-Q (Meq)–Encoded Oncoprotein: Characterization of an rMd5-Based Mutant Expressing the Meq of Strain RB-1B
US20160263210A1 (en) Live attenuated infectious laryngotracheitis virus (iltv) vaccines and preparation thereof
Boratynska et al. Contribution of rearranged actin structures to the spread of Ectromelia virus infection in vitro
Taranov et al. Study of cultural characteristics and interference of Peste des Petit ruminants virus and sheep pox virus in co-culture
RU2760399C1 (ru) Аттенуированный штамм "ASFV/CV60/2020" вируса африканской чумы свиней семейства Asfarviridae, рода Asfivirus для изучения иммунологических реакций, молекулярно-генетического анализа, генетической модификации и создания прототипа вакцины против АЧС